Search

Each record is a registered study, a systematic-review registration or a publication. A registered or ongoing study is not a finding, and animal or cell research does not show an effect in people. The same study can appear under more than one subject, so the number of records is not a count of independent studies. You can also search an exact DOI, PubMed ID, NCT or CRD number. How to read these records.

31 study records (showing up to 30 per record type)

• Registered trial NCT05806307 Phase 4 Not completed: Recruiting
  Methods Decreasing Bleeding in Open Myomectomy
  Condition or outcome area: Misoprostol Allergy|Oxytocin Allergy|Tranexamic Acid Allergy|Ethamsylate Allergy|Myoma|Blood Loss, Surgical
  2023-03-15 · Subject: Vasopressin; Pressyn · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05806307 Phase 4 Not completed: Recruiting
  Methods Decreasing Bleeding in Open Myomectomy
  Condition or outcome area: Misoprostol Allergy|Oxytocin Allergy|Tranexamic Acid Allergy|Ethamsylate Allergy|Myoma|Blood Loss, Surgical
  2023-03-15 · Subject: Oxytocin · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05940233 Not completed: Recruiting
  Comparison of Rate of Complete Abortion Between Letrozole Plus Misoprostol vs Misoprostol Alone
  Condition or outcome area: Medical; Abortion, Fetus
  2023-06-30 · Subject: Femara; Letrozole; Benzonitrile, 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-; BSPBio_001209; CGS-20267; C08163; Prestwick2_001025; CAS-112809-51-5; 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile; BPBio1_001331 · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05806307 Phase 4 Not completed: Recruiting
  Methods Decreasing Bleeding in Open Myomectomy
  Condition or outcome area: Misoprostol Allergy|Oxytocin Allergy|Tranexamic Acid Allergy|Ethamsylate Allergy|Myoma|Blood Loss, Surgical
  2023-03-15 · Subject: Adrenaline; Epinephrine hydrochloride; adrenaline · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05568745 Phase 4 Not completed: Recruiting
  Balloon + Oxytocin Versus Oral Misoprostol to Induce Labor in Case of PROM (RUBAPRO2)
  Condition or outcome area: Induction of Labor|Cervical Ripening|Premature Rupture of Fetal Membranes|Nulliparous
  2023-01-18 · Subject: Oxytocin · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05207644 Phase 2 Completed (results not assessed here)
  Letrozole and Misoprostol for Termination of Pregnancy up to 63 Days' Gestation
  Condition or outcome area: Pregnancy
  2021-12-09 · Subject: Femara; Letrozole; Benzonitrile, 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-; BSPBio_001209; CGS-20267; C08163; Prestwick2_001025; CAS-112809-51-5; 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile; BPBio1_001331 · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05083910 Completed (results not assessed here)
  Randomization of Oxytocin, Oxytocin+Intrauterine Misoprostol and Carbetocin During C-section
  Condition or outcome area: Postpartum Hemorrhage
  2021-07-01 · Subject: Oxytocin · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT04492072 Completed (results not assessed here)
  Misoprostol With Mechanical Dilation Versus Oxytocin With Mechanical Dilation for High-risk Pregnancy Inductions
  Condition or outcome area: Cesarean Section|Misoprostol|Oxytocin|High Risk Pregnancy
  2020-08-17 · Subject: Oxytocin · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT03870503 Completed (results not assessed here)
  Carbetocin Versus Oxytocin Plus Sublingual Misoprostol in the Management of Atonic Postpartum Hemorrhage
  Condition or outcome area: Postpartum Hemorrhage
  2019-04-01 · Subject: Oxytocin · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT03676621 Phase 4 Completed (results not assessed here)
  Buccal Misoprostol Versus IV Oxytocin in Prevention of Postpartum Hemorrhage
  Condition or outcome area: Postpartum Hemorrhage
  2018-11-01 · Subject: Oxytocin · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT03148574 Phase 3 Completed (results not assessed here)
  Intrauterine Misoprostol Versus Intravenous Oxytocin Infusion During Cesarean Delivery
  Condition or outcome area: Post Partum Hemorrhage
  2017-07-02 · Subject: Oxytocin · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT02786992 Phase 2 / Phase 3 Completed (results not assessed here)
  Misoprostol+Oxytocin vs. Carbetocin in CS
  Condition or outcome area: Cesarean Section
  2016-05 · Subject: Oxytocin · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT04037683 Completed (results not assessed here)
  qMOLI- A Qualitative Assessment of Misoprostol or Oxytocin for Labour Induction
  Condition or outcome area: Pre-Eclampsia
  2019-10-18 · Subject: Oxytocin · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT04028765 Phase 4 Completed (results not assessed here)
  Pitocin or Oral Misoprostol for PROM IOL
  Condition or outcome area: PROM
  2019-08-12 · Subject: Oxytocin · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT03749902 Phase 4 Completed (results not assessed here)
  A Randomized Trial of Oral Misoprostol Alone Versus Oral Misoprostol Followed by Oxytocin for Labour Induction
  Condition or outcome area: Induction of Labor
  2020-01-06 · Subject: Oxytocin · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT02983591 Completed (results not assessed here)
  Effect of Misoprostol in Reducing Post Partum Hemorrhage After Labor Induction by Oxytocin
  Condition or outcome area: Prevention of Post Partum Hemorrhage After Labor Induction
  2016-11 · Subject: Oxytocin · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT01863706 Phase 1 Completed (results not assessed here)
  Misoprostol Versus Oxytocin for Prevention of Post Partum Hemorrhage
  Condition or outcome area: Post Partum Hemorrhage
  2013-05 · Subject: Oxytocin · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT01571323 Phase 1 / Phase 2 Completed (results not assessed here)
  Combined Use of Oxytocin and Misoprostol Versus Oxytocin Infusion and Misoprostol Alone to Reduce Blood Loss at Cesarean Section
  Condition or outcome area: Post Partum Haemorrhage
  2012-02 · Subject: Oxytocin · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT01373359 Phase 3 Completed (results not assessed here)
  Prevention of Postpartum Haemorrhage With Sublingual Misoprostol or Oxytocin
  Condition or outcome area: Postpartum Hemorrhage
  2007-03 · Subject: Oxytocin · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT01139801 Completed (results not assessed here)
  Cervical Ripening for Induction of Labor: Misoprostol Versus Oxytocin in Conjunction With Foley Balloon
  Condition or outcome area: Induction of Labor
  2009-09 · Subject: Oxytocin · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT00784797 Phase 4 Completed (results not assessed here)
  Misopristol Versus Pitocin for Second Trimester Abortion
  Condition or outcome area: Abortion, Missed
  2009-01 · Subject: Oxytocin · open the ingredient record · ClinicalTrials.gov
• Systematic review registration CRD42021230367 Registered protocol, no results here: Review Ongoing
  The efficacy of Shenghua Decoction supplementation after early medical abortion: a meta-analysis of randomized controlled trials
  Condition or outcome area: Medical abortion, which recommended by the World Health Organization (WHO) using a combination of mifepristone followed by misoprostol, is increasingly being used to end an early pregnancy with approximately 98% effective, and considered as a safe, noninvasive, affordable and acceptable alternative worldwide over traditional dilatation and curettage. Despite excellent effectiveness and safety, incomplete abortion and excessive and prolonged uterine bleeding are among the major limitations in suc
  2021-02-09 · Subject: Sheng Hua Tang; 生化汤; Sheng Hua Decoction · open the formula record
• Systematic review registration CRD42022320179 Registered protocol, no results here: Review Ongoing
  The efficacy and safety of Shenghua Decoction combined with Mifepristone and Misoprostol in the treatment of missed miscarriage: A systematic review and meta-analysis
  Condition or outcome area: Miscarriage is common, affecting one in five pregnancies.Miscarriage can cause physical harm, such as excessive bleeding and infection so on. Medical management are alternatives to surgical evacuation.Randomized trials comparing medical treatment, most often mifepristone and misoprostol(MifeMiso), are commonly used for the medical management of miscarriage to induce myometrial contractions to aid the expulsion of pregnancy tissue.However, MifeMiso are not always effective, and 15–40% of women re
  2022-05-10 · Subject: Sheng Hua Tang; 生化汤; Sheng Hua Decoction · open the formula record
• Systematic review registration CRD42022363622 Registered protocol, no results here: Review Ongoing
  Oxytocin versus rectal misoprostol for cesarean section: Meta-analysis of randomized controlled trials
  Condition or outcome area: prevention of blood loss during CS
  2022-10-09 · Subject: Oxytocin; 50-56-6; Pitocin; Endopituitrina; Ocytocin; Syntocinon; Oxytocinum; Orasthin; Oxystin; alpha-Hypophamine · open the ingredient record
• Systematic review registration CRD42022323812 Registered protocol, no results here: Review Ongoing
  Healthcare providers´ perception of the quality of oxytocin and misoprostol: a mixed methods systematic review
  Condition or outcome area: Post-partum hemorrhage (PPH) is a leading cause of maternal mortality and morbidity, especially in low- and middle-income countries (LMICs). PPH can be prevented with routine administration of prophylactic uterotonics (drugs that promote uterine contraction) such as oxytocin (drug of choice) or misoprostol. There is evidence that the quality of oxytocin and misoprostol is suboptimal in many settings, especially in LMICs. There have been reports that some healthcare providers (HCP) perceive recom
  2022-05-07 · Subject: Oxytocin; 50-56-6; Pitocin; Endopituitrina; Ocytocin; Syntocinon; Oxytocinum; Orasthin; Oxystin; alpha-Hypophamine · open the ingredient record
• Systematic review registration CRD42019133611 Registered protocol, no results here: Review Ongoing
  Concurrent administration of oxytocin with foley catheter versus misoprostol for induction of labor in singleton full term pregnancies
  Condition or outcome area: Induction of Labor: Induction of labor is a common procedure all over the world. In USA, the rate of induction of labor is about 25.8% in 2015. In England and Wales the rate of induction of labor is about 23.3%. The most common reasons for induction of labor includes: post term pregnancies, premature rupture of membranes, preeclampsia, ..etc. Induction of labor could be complicated with chorioamnionitis, hyperstimulation, fetal distress, or uterine rupture in patients with previous uterine scar
  2019-06-12 · Subject: Oxytocin; 50-56-6; Pitocin; Endopituitrina; Ocytocin; Syntocinon; Oxytocinum; Orasthin; Oxystin; alpha-Hypophamine · open the ingredient record
• Systematic review registration CRD42018107227 Registered protocol, no results here: Review Ongoing
  Comparative efficacy and safety of dinoprostone, misoprostol and isosorbide mononitrate (IMN) for cervical ripening in outpatient settings: a systematic review and network meta-analysis
  Condition or outcome area: Try to find the best treatment for cervical ripening in outpatient setting.
  2018-08-28 · Subject: Isosorbide; 652-67-5; Isobide; Ismotic; Devicoran; Hydronol; Sorbid; (3R,3aR,6S,6aR)-hexahydrofuro[3,2-b]furan-3,6-diol; (+)-D-Isosorbide; 1,4:3,6-Dianhydro-D-glucitol · open the ingredient record
• Systematic review registration CRD42014013196 Registered protocol, no results here: Review Ongoing
  Misoprostol versus ergometrine-oxytocin for preventing postpartum hemorrhage: systematic review and meta-analysis of randomized controlled trials and the implications for developing countries
  Condition or outcome area: Postpartum hemorrhage (PPH) is a major cause of maternal mortality, accounting for more than 100,000 maternal deaths per year. PPH also results in long-term disabilities and severe maternal morbidities. An estimated 287 000 maternal deaths occurred worldwide in 2010, among those pregnant women in sub-Saharan Africa (56%) and southern Asia (29%) accounted for 85% of the global burden in 2010. The United Nations aims to reduce maternal mortality by 75% by 2015. Thus far, the progress is slow in de
  2014-08-13 · Subject: Oxytocin; 50-56-6; Pitocin; Endopituitrina; Ocytocin; Syntocinon; Oxytocinum; Orasthin; Oxystin; alpha-Hypophamine · open the ingredient record
• Systematic review registration CRD42014013196 Registered protocol, no results here: Review Ongoing
  Misoprostol versus ergometrine-oxytocin for preventing postpartum hemorrhage: systematic review and meta-analysis of randomized controlled trials and the implications for developing countries
  Condition or outcome area: Postpartum hemorrhage (PPH) is a major cause of maternal mortality, accounting for more than 100,000 maternal deaths per year. PPH also results in long-term disabilities and severe maternal morbidities. An estimated 287 000 maternal deaths occurred worldwide in 2010, among those pregnant women in sub-Saharan Africa (56%) and southern Asia (29%) accounted for 85% of the global burden in 2010. The United Nations aims to reduce maternal mortality by 75% by 2015. Thus far, the progress is slow in de
  2014-08-13 · Subject: Ergonovine; Ergometrine; Ergobasine; Ergotocine; Ergostetrine; Ergometrin; Margonovine; 60-79-7; Ergotrate; Ergoklinine · open the ingredient record
• Systematic review registration CRD42014013196 Registered protocol, no results here: Review Ongoing
  Misoprostol versus ergometrine-oxytocin for preventing postpartum hemorrhage: systematic review and meta-analysis of randomized controlled trials and the implications for developing countries
  Condition or outcome area: Postpartum hemorrhage (PPH) is a major cause of maternal mortality, accounting for more than 100,000 maternal deaths per year. PPH also results in long-term disabilities and severe maternal morbidities. An estimated 287 000 maternal deaths occurred worldwide in 2010, among those pregnant women in sub-Saharan Africa (56%) and southern Asia (29%) accounted for 85% of the global burden in 2010. The United Nations aims to reduce maternal mortality by 75% by 2015. Thus far, the progress is slow in de
  2014-08-13 · Subject: Ergometrine; Ergonovine; ERGONOVINE; Ergobasine; Ergotocine; Ergostetrine; Ergometrin; Margonovine; 60-79-7; Ergotrate · open the ingredient record
• Publication PMID 33525359 Research model: Animal Experiment
  Fatty Acids and a High-Fat Diet Induce Epithelial-Mesenchymal Transition by Activating TGFβ and β-Catenin in Liver Cells
  Condition or outcome area: Nonalcoholic fatty liver disease; hepatocarcinoma; Fibrosis; liver cirrhosis; liver fibrosis; hepatocellular carcinoma; chronic liver inflammation; fibrosis; hepatocarcinogenesis; steatosis; steatohepatitis
  Int J Mol Sci · 2021 · Subject: Saturated fatty acids; Formic Acid; formic acid; Methanoic acid; 64-18-6; Formylic acid; Aminic acid; Bilorin; Hydrogen carboxylic acid; Formisoton · open the ingredient record · DOI 10.3390/ijms22031272